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Abstract  
Based on the high volume of bacteria and viruses that the intestine is exposed to and the 
importance of infectious agents in some gastrointestinal and anogenital cancers, it is not 
surprising the many studies have evaluated the association between colorectal cancer and 
infectious agents.  This review highlights investigations of four agents in relation to 
colorectal cancer; Helicobacter pylori, Streptococcus bovis, JC virus (JCV), and human 
papillomavirus (HPV) have all been evaluated as possible etiologic agents for colorectal 
cancer.  For each of these agents, a review of possible mechanisms for carcinogenesis and 
epidemiologic evidence is discussed, and future directions for research are proposed.   
 
Introduction 
 
Since the 1980s, there has been a dramatic increase in research on infections and cancer.  
In 2002, it was reported that infectious agents accounted for approximately 18% of all 
cancers worldwide (1).  This estimate is based on the burden of disease associated with 
cancers that have known infectious etiologies, such as cervical, liver, and gastric cancers.  
However, as the technology to detect infectious agents improves and more studies are 
conducted, future research may reveal new associations between cancer and infection, 
and the proportion of cancers attributable to infection may rise.  Furthermore, linking 
cancers to specific infectious agents may provide new avenues for effective cancer 
prevention, in particular vaccination.  
 
In 2002, there were approximately 1 million new cases of colorectal cancer worldwide, 
accounting for 9.4% of all cancer (2). Colorectal cancer is the fourth most common 
cancer among men and third most common among women worldwide (2); nonetheless, 
much is still uncertain about its etiology.  It is established that colorectal cancer has a 
strong association with certain hereditary gene mutations, but only 3-5% of colorectal 
cancers are due to these known mutations alone(3). Cigarette smoking, high alcohol 
consumption, low vegetable intake, obesity, and physical inactivity are associated with an 
increased risk of colorectal cancer; post-menopausal hormone use, non-steroidal 
inflammatory drug use, and high calcium intake are associated with a reduced risk(4).  
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Colorectal cancer originates in the epithelial cells lining the colon and rectum.  The cells 
of the human colon replicate at a relatively high rate with 1010 epithelial cells being 
replaced every day (5).  This high rate of replication is thought to contribute to the 
vulnerability of colon and rectal epithelium to mutation and consequent carcinogenesis, 
although this elevated risk does not seem to apply to the small intestine, despite 
comparably elevated cell turnover.  If colonic epithelial cells accumulate mutations in 
oncogenes and tumor suppressor genes, the morphology of the cell changes, and there is a 
hyperproliferation of abnormal cells (6).  This can result in a neoplastic growth, known as 
a polyp.  Adenomatous polyps (adenomas) are benign lesions in the colon and rectum 
that have the potential to develop into cancer (7).  Other pathways for colorectal cancer 
include those involving hyperplastic polyps  (8-10) and ulcerative colitis (11). 
 
The human intestine provides a habitat that is rich in nutrients, permitting for the growth 
of over 500 different species of bacteria, with the highest concentration of bacteria found 
in the colon (12).  In addition to bacteria, the human colon is frequently exposed to both 
pathogenic and non-pathogenic viruses.  Normally, the bacteria found in the colon have a 
symbiotic relationship with their host and can even provide some protection against 
pathogens (12).  However, some microbes that are normally or incidentally found in the 
colon are pathogenic or potentially pathogenic if they breech the host mucosal barrier.   
 
Due to the sheer numbers of microbes found in the colorectum and the recent interest in 
infectious agents as a cause of cancer, it is not surprising that researchers have begun, 
again, to consider infectious agents as a possible cause of colorectal cancer.  In this 
article, we review the evidence on four infectious agents that have been most commonly 
studied in relation to colorectal cancer: Helicobacter pylori, Streptococcus bovis, JC virus 
(JCV), and human papillomavirus (HPV).  For each infectious agent, we conducted a 
search of PubMed and reviewed all relevant studies with a manuscript or abstract written 
in English published prior to 2008. 
 
Helicobacter pylori 
 
Infection with Helicobacter pylori usually occurs at a young age and is extremely 
common, with one study showing that 49% of the people pooled from 17 populations 
across the world had antibodies to H. pylori (13).  However, there is tremendous 
geographic variation in the prevalence of H. pylori infection with some of the highest 
infection rates nearing 90% in parts of Japan and the lowest infection rates around 33% in 
the United States (13).  In addition, H. pylori infection is associated with low 
socioeconomic status, and person-to-person transmission is thought to be the dominant 
mode of transmission (14).  Also, H. pylori infection prevalence varies markedly by age, 
either as a result of a cohort effect in which older generations were exposed to higher 
rates of H. pylori transmission or (less likely) accumulating risk of infection with age 
(13). 
 
H. pylori is a gram-negative bacterium that has become well adapted to the human 
stomach via interaction with gastric epithelial cells (15).  Chronic gastric infection with 
H. pylori causes inflammation and several gastric pathologies, including gastric ulcers 
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and gastric cancer  (16-18).  Carcinogenesis via H. pylori involves inflammation, as well 
as deregulation of the cell cycle via the H. pylori protein, CagA, which binds and 
activates SHP2 (a human phosphatase that can act as an oncoprotein) resulting in cell 
growth and motility (18).  Due to the strong association between H. pylori and gastric 
cancer, H. pylori is classified as a class I carcinogen by the International Agency for 
Research on Cancer (19).   
  
Despite the established relationship between H. pylori and gastric pathologies, the 
association between H. pylori and colorectal cancer is much less clear.  Epidemiologic 
studies have used serology, polymerase chain reaction (PCR) methods, C-urea breath 
tests (C-UBT) and circulating gastrin levels to examine colorectal neoplasia in relation to 
H. pylori infection and have produced conflicting results. 
 
We reviewed 16 epidemiologic studies examining associations between colorectal 
adenomas or adenocarcinomas and H. pylori seroprevalence.  Six of these studies found 
statistically significantly associations between H. pylori antibodies and colorectal 
neoplasia with odds ratio (OR) estimates ranging from 1.4 to 4.0 (20-25).  However, the 
other 10 studies did not find a statistically significant association between H. pylori 
seropositivity and colorectal neoplasia (26-35).  Most of these null studies reported OR 
estimates between 1.0 and 1.5 (26, 28, 30-32, 34, 35).  Only one of these studies reported 
an inverse association between H. pylori and colorectal neoplasia (OR=0.7; 95% CI=0.3-
2.0) (27). 
 
A recent meta-analysis examining studies published between 1991 and 2002 to determine 
the relationship between H. pylori and colorectal neoplasia found an overall statistically 
significant association between H. pylori and the risk of colorectal neoplasia (OR=1.4; 
95% CI=1.1-1.8) (36).  However, there is skepticism of this association, because the 
geographic distribution of colorectal cancer does not mirror that of gastric cancer, and in 
many areas, most notably in Japan, there are opposing trends over time for these two 
cancers (37, 38).  
  
Discrepancies in the results between studies could be attributed to differences in the 
selection of controls, variation in adjustment for confounding variables, and limited 
power to detect associations due to small sample sizes in most of the studies.  However, 
one study attributes these variable results to differences in the prevalence of cytotoxin-
associated gene-A-positive (CagA+) strains of H. pylori between the populations studied 
(30).  Studies of gastric cancer indicate that H. pylori CagA+ strains are more likely to 
cause inflammation and malignancy than CagA- strains (39, 40).   Therefore, the 
Shmuely study compared CagA status between 41 colorectal adenocarcinoma patients 
seropositive for H. pylori and 24 hospital-based controls also seropositive for H. pylori.  
Infection with a CagA+ strain was associated with a statistically significant increased risk 
of colorectal adenocarcinoma (OR=10.6; 95% CI = 2.7-41.3) compared to infection with 
a CagA- strain.  Although the design of this study is limited because it is hospital-based 
rather than population-based, it underscores the importance of examining pathogen 
characteristics as possible risk factors for disease.  Not all H. pylori strains have the same 
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virulence, so combining mild strains together with more virulent strains may dilute 
possible associations. 
 
Although serology is the most common approach used to assess the relationship between 
H. pylori and colorectal cancer, several other techniques have been used.  C-urea breath 
tests (C-UBT) can detect current gastric H. pylori infection with approximately 97% 
sensitivity and specificity (41).  A Taiwanese study using this method found no 
association between current H. pylori infection and colorectal adenomas (42).  However, 
another study in Japan using C-UBT, urease detection in biopsy specimens, or other 
histologic tests of biopsied gastric tissue to assess current infection with H. pylori found 
positive associations (OR=1.60; 95% CI=1.18-2.02 for adenomas and OR=1.80; 95% CI 
= 1.28-2.32 for adenocarcinomas).  This association was modified by sex, with a stronger 
association among women (43).   
  
Using PCR methods, one study found that 1.2% of malignant colorectal tissues (N=83) 
were positive for H. pylori, whereas 6.0% of normal tissues were positive (N=83) (44).  
Therefore, the authors concluded that H. pylori is not important in the pathogenesis of 
colorectal cancer.  However, two other studies that used PCR to detect H. pylori in 
colorectal neoplasms indicated that a much greater proportion of these tissues were 
positive for H. pylori: one study detected H. pylori DNA in 27% of colorectal 
adenocarcinoma tissues (45); another found that detection of H. pylori DNA in colorectal 
tissue was associated with an increased risk of colorectal adenocarcinomas (OR= 8.13; 
95% CI=1.4-47.0) (46). 
   
It could be that it is not infection of colorectal tissue with H. pylori that may be 
responsible for an increased risk of colorectal cancer, but rather the byproducts of a 
gastric H. pylori infection (22).  One theory stems from the fact that gastric H. pylori 
infection increases serum levels of gastrin leading to hypergastrinemia (47).  Because 
hypergastrinemia is hypothesized to have proliferative effects on intestinal mucosa (48), 
some studies have assessed the relationship between serum gastrin levels and colorectal 
cancer risk.   Several studies found a positive association between hypergastrinemia and 
colorectal neoplasia (22, 28, 33), including a prospective study assessing serum gastrin 
levels prior to the diagnosis of colorectal carcinoma (OR=3.9; 95% CI=1.5-9.8) (28).  
  
If H. pylori is a cause of colorectal carcinoma, it is clear that the association is complex 
and perhaps mediated through pathogen-virulence factors.  Future research addressing the 
relationship between H. pylori and colorectal neoplasia should be prospective and make 
attempts to increase the sensitivity of studies by focusing on the subsets of H. pylori that 
are most likely to cause malignancy and/or subsets of colorectal cancers that are most 
likely to be associated with infection or inflammation.  In addition, studies should 
evaluate gastric H. pylori infection as a possible risk factor for colorectal neoplasia. 
  
Streptococcus bovis 
 
Streptococcus bovis, a nonenterococcal group D Streptococcus, is a bacterium that is 
found among the normal flora of the human gastrointestinal tract in 5-16% of adults (49).  
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In addition, S. bovis is commonly detected as a contaminant in packaged meat (50).  If S. 
bovis enters the blood stream, it can cause bacteremia and endocarditis; approximately 
11-12% of infective endocarditis is caused by S. bovis (51, 52).  Endocarditis caused by 
S. bovis is more common in men and in the elderly (53).  In two studies, patients with 
endocarditis caused by S. bovis type I, recently reclassified as Streptococcus gallolyticus, 
have an increased risk of prevalent colorectal neoplasia (54) (55). 
 
Laboratory studies of S. bovis reveal that this bacterium releases proteins which stimulate 
inflammation (56).  In addition, S. bovis proteins were associated with an in vitro over-
expression of COX-2 (56), which is known to be frequently over-expressed in human 
colorectal cancers and which can inhibit apoptosis and increase angiogenesis (57). 
     
The debate over the association between S. bovis and colonic neoplasia has a long 
history, going back as early as 1951 when the first case report of colon cancer associated 
with enterococcal endocarditis was published (58).  Since then, numerous studies and 
case reports have linked S. bovis bacteremia and endocarditis with colon polyps and 
carcinomas (59-72).  In a review of studies evaluating patients with S. bovis bacteremia 
who were examined for gastrointestinal disease, Gold et al noted that studies reported 
between 6% and 71% of those with S. bovis bacteremia had colonic neoplasia (71).  Due 
to the high prevalence of colonic neoplasia in those with S. bovis bacteremia or 
endocarditis, colonoscopy to screen for occult colorectal cancer and pre-cancerous 
lesions has been recommended in this group (60, 62, 63, 65, 70, 71).  
 
In addition, several cross-sectional studies have examined the association between S. 
bovis endocarditis and colonic neoplasia.  A 1987 study found statistically significantly 
higher risks of colon polyps and colon cancer among 34 patients with S. bovis 
endocarditis  compared to 43 patients with endocarditis caused by other bacteria (35% vs. 
7% for polyps and 26% vs. 2% for cancer) (66).  Since then, two additional studies have 
confirmed these results (68, 69).  The Hoen et al study compared the prevalence of colon 
polyps and colon cancer in 32 colonoscopy screened cases of S. bovis endocarditis and 64 
age and sex-matched controls without S. bovis endocarditis also screened via 
colonoscopy: 47% of S. bovis endocarditis patients had colon adenomas vs. 23% of those 
without S. bovis endocarditis, and 9% of S. bovis endocarditis cases had colorectal cancer 
compared to 3% of those without S. bovis endocarditis (68).  The Pergola et al study 
examined colorectal neoplasia in 40 cases of S. bovis endocarditis and 166 patients with 
infective endocarditis caused by other bacterium: colorectal neoplasia was present in 55% 
of S. bovis endocarditis cases but in only 4% of other infective endocarditis cases (69).  
Although the above studies have been small, all suggest an association between S. bovis 
endocarditis and colorectal neoplasia.   
 
Other studies examining the presence of S. bovis in stool and the risk of colorectal cancer 
have produced conflicting results.  A study by Klein et al found that 35 of 63 colon 
cancer cases had S. bovis present in their stool compared to 11 of 105 hospital-based 
controls (OR=10.7; 95% CI = 4.8-23.7) (59).  This finding was confirmed in a later study 
on a separate population (73).  However, three studies found no association between the 
presence of S. bovis in stool and colorectal neoplasia (74-76).  
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Serologic studies assessing the association between S. bovis antibodies and colonic 
neoplasia have been performed.  A 1993 study examining serum samples from 16 colon 
cancer cases and 16 age-matched controls whose sera was being tested for rheumatoid 
factor and anti-nuclear factor found that cases had a statistically significantly higher 
median IgG antibody titer to S. bovis than controls; however, IgM antibody titers were 
similar between the two groups (77).  The authors concluded that immune stimulation 
caused by S. bovis occurred over a long period of time and was not a recent occurrence 
due to advanced clinical disease.  Another study by Tjalsma et al found S. bovis 
antibodies in 11 out 12 colon-cancer patients, in 3 out of 4 colon-polyp patients, and in 0 
out of 8 control subjects; antibodies to another bacterium commonly found in the human 
gut, E. coli, were not found more commonly in cases than controls (78).  
 
Based on this body of evidence, there is a strong association between S. bovis bacteremia 
and colorectal neoplasia.  However, many debate the temporality of this association.  One 
view is that ulcerating colorectal carcinomas allow increased growth of S. bovis, invasion 
of the blood stream, and establishment of infection (59).  Others argue that S. bovis is a 
direct cause of colon carcinogenesis.  Supporters of the latter argument point to the fact 
that pre-cancerous polyps, and not just ulcerative carcinomas, are associated with S. bovis 
(73, 78).  Furthermore, a 1982 study found an increased risk of subsequent colonic 
neoplasia among those with previous S. bovis endocarditis (63).  Finally, molecular 
evidence points towards S. bovis as a possible carcinogen in a rat model (56, 79).   
 
Despite this evidence, large gaps exist in the literature assessing the relationship between 
S. bovis and colon cancer.  There are currently no published case-control studies using 
PCR to detect S. bovis in colorectal tissue from cases and controls.  In addition, S. bovis 
type I is the subtype of S. bovis that is most commonly associated with colorectal 
neoplasia in patients with S. bovis bacteremia (54, 55).  However, most colorectal cancer 
epidemiology studies have not classified S. bovis according to subtype.  Therefore, 
studies may dilute a possible association by combining the more pathogenic subtype, type 
I, with less pathogenic subtypes.  Finally, large prospective studies are absent from the 
literature.  Because colorectal cancer screening has become relatively common, 
prospective studies of S. bovis colorectal infection and later development of colorectal 
neoplasia are feasible and should be pursued. 
 
JC Virus 
 
Human infection with the polyomavirus, JC virus (JCV), is extremely common, affecting 
up to 80% of the population (80).  Although the route of transmission for JCV is 
unknown, primary infection generally occurs in early childhood.  The vast majority of 
those infected with JCV have no symptoms, and the virus travels to the kidneys, where it 
remains latent (81).  However, severe immunsupression, as seen in transplant patients and  
those with advanced HIV disease, can trigger reactivation of the virus causing a serious 
demyelinating disease known as progressive multifocal leukoencephalopathy (PML) (82, 
83). 
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The oncogenic properties of JCV are well described in the literature and attributed to the 
viral protein, large T-antigen.  Laboratory studies of this viral protein have demonstrated 
that the large T-antigen has the ability to immortalize cells in culture (84, 85). The 
mechanism for this cellular transformation has been studied: the large T-antigen binds 
p53 and members of the pRb family of proteins, thereby blocking tumor suppression and 
inducing unchecked cellular replication (86, 87).  This is hypothesized to result in 
chromosomal instability, which is common in colon carcinogenesis (88). 
  
Despite molecular evidence showing the potential for JCV to induce carcinogenesis, there 
is not a strong consensus linking JCV to human cancers.  Most of the studies involving 
JCV and cancer have been conducted in tumors of the CNS and, although many detect 
the presence of JCV in CNS tumors, most of these studies have examined only case tissue 
and did not compare their results to separate disease-free controls (89-91). 
  
Recently, attention has turned to examining JCV in relation to colorectal neoplasia.  
Several studies have demonstrated the presence of JCV in both normal and neoplastic 
tissues from the colon and rectum (92-95).  One of the earliest studies to detect JCV 
DNA via PCR in colorectal epithelial tissues was published in 1999.  This study found 
that, although JCV DNA was in both cancerous and normal colon tissue, the viral copy 
number was statistically significantly higher in the cancerous cells.  In addition, these 
researchers recommended the use of topoisomerase I treatment to improve PCR 
sensitivity for detecting JCV.  Because JCV contains a supercoiled DNA genome, 
topoisomerase I is thought to relax the supercoiling and allow better detection and 
amplification of JCV DNA sequences by PCR (92). 
  
Since then, several studies have examined the presence of JCV DNA in colonic tissue 
using PCR.  A study by Ricciardiello et al in 2000 confirmed the presence of JCV in the 
upper and lower gastrointestinal (GI) tract using normal GI tissue samples from 33 
patients.  This study detected JCV DNA sequences in the upper GI for 70.6% of patients 
and in the lower GI for 81.2% of patients and concluded that infection of the GI track 
with JCV is common in those without immune suppression (93).   
 
In addition, we reviewed five studies examining colorectal neoplastic tissue detecting 
JCV DNA in colorectal neoplasias at varying frequencies, finding from 26% to 89% of 
carcinomas positive for JCV (94-98).  Two of these studies also tested colorectal 
adenomatous tissue from separate patients with adenomas and normal colorectal tissues 
from controls.  One study found JCV infection in 61% of cancerous tissue (N=80), 60% 
of adenomatous tissue (N=25) and 30% of normal tissue samples from controls (N=20), 
resulting in an OR = 6.2 (95% CI = 2.4-16.6) comparing neoplastic tissue to normal 
tissue.  This same study found JCV viral copy numbers were statistically significantly 
higher in neoplastic colorectal tissue compared to normal colorectal tissue (94).  The 
other study had lower rates of detection for JCV, finding 26% of cancerous colorectal 
tissue (N=23), 5% of adenomas (N=21) and 0% of normal tissue (N=20) positive for JCV 
(95).  
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Two studies found no association between JCV and colorectal cancer using PCR (99, 
100).  One of these null studies tested 233 cancerous colorectal tissue samples and 233 
normal surrounding colorectal tissue samples from the same patients using a lab that had 
never previously been used for JCV or other viral studies; only 1 normal colorectal 
specimen was positive for JCV (100).  The authors concluded that there is no association 
between colorectal cancer and JCV, and that previous studies detecting JCV in colonic 
tissue may have had problems with contamination due to the ubiquity of JCV.   
 
Recently, a nested case-control study tested blood samples collected at least 3 months 
prior to cancer diagnosis in 386 male cases of colorectal cancer and 386 matched controls 
and found no association between JCV seropositivity and colorectal cancer (OR = 0.9; 
95% CI = 0.7-1.3) (101).  Although this test was sensitive for detecting exposure to JC 
virus, it was not specific to the detection of colonic JCV infection.  Because JCV 
infection is so common, it is important to identify infection site.   
 
Despite the inconsistencies in the epidemiologic evidence, there is molecular evidence 
that the JC virus large T-antigen causes chromosomal mutations resulting in 
chromosomal instability in colonic epithelial cell lines in vitro (102).  In addition, 
Ricciardello et al demonstrated that a specific subset of JCV, the Mad-1 strain, is the only 
type of JC virus found in the colon and that a specific variant of this strain (a variant 
lacking a 98-bp repeat) is associated with colorectal cancer (103).  If this finding is 
confirmed, differentiating this subset of JCV from other potentially non-pathogenic types 
will be important in establishing an etiologic association between JCV and colorectal 
cancer. 
 
Future studies need to establish a standard, reliable, and reproducible test for the 
detection of JC virus DNA.  This test should be evaluated in masked specimens, multiple 
populations, and different laboratories to insure the validity of the results.  In addition, 
prospective studies of fecal carriage of JC virus in relation to colorectal cancer are absent 
from the literature.  Such studies could help determine specificity, and possibly causality, 
in the association between JC virus and colorectal cancer if fecal carriage of virulent JCV 
subtypes occurs prior to the development of colorectal neoplasia and at higher rates in 
cases than controls.  
 
Human papillomavirus  
 
HPV is a double-stranded DNA virus that infects basal-layer epithelial cells through 
microscopic abrasions or tears (104).  There are more than 100 types of HPV, and about 
40 of these types are known to infect genital epithelial cells (105).  Genital HPV is 
transmitted via sexual contact and is the most common sexually transmitted infection 
among Americans ages 15-49 years of age (106, 107).  For most people, anogenital HPV 
infections resolve on their own and have few to no clinically apparent symptoms (108).  
However, women who are unable to clear cervical HPV infection and are persistently 
infected with certain types of HPV are at increased risk for the development of cancer 
(108).  
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Not all types of HPV are associated with cancer.  Currently, types 16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, 68, 73, and 82 are classified as “high-risk” oncogenic infections 
(104).  Of these, types 16 and 18 are the most common types found in cervical cancer 
tumors, with one review finding that approximately 70% of cases were positive for HPV-
16, 18 or both (109).  HPV infection is a necessary cause of cervical cancer and is 
associated with other epithelial malignancies, such as oropharyngeal, penile, vaginal, 
vulvar, and anal cancer (110-112).  Although 100% of cervical cancer is attributable to 
HPV, other anogenital cancers vary in the proportion of site-specific cancer positive for 
“high-risk” HPV (111). 
 
Oncogenic HPV allows for the growth of cancerous cells through the expression of viral 
proteins E6 and E7.  These interfere with tumor suppressor proteins, p53 and pRb, and 
induce telomerase, thereby immortalizing cells (111).  Thus, HPV-related tumors 
infrequently contain p53 mutations (113).  Infection with “high-risk” HPV, however, is 
not sufficient by itself to cause cancer.  Additional cellular alterations are necessary for 
tumorigenesis, and an accumulation of mutations appear to occur over time (111).   
 
Early case-only studies of colorectal neoplastic tissue failed to detect HPV DNA (114-
117).  However, the sample size in each of these studies was small, ranging from 10 to 50 
cases.  In addition, HPV detection techniques have improved, and more recent studies of 
the association between HPV and colorectal neoplasia suggest a positive association. 
 
We reviewed 9 case-control studies of the association between HPV and colorectal 
neoplasia. Studies varied by the type of tissue analyzed, with some including carcinomas, 
others adenomas, and still others both.  In addition, control tissues varied among studies 
and included: adjacent normal tissue from cases, benign colon polyps from separate 
individuals, and normal colon tissue from disease-free controls. Eight of these studies 
used PCR techniques to detect HPV DNA in colorectal neoplastic tissues and control 
tissues (118-125).  One study used immunohistochemistry to detect HPV antigen in case 
and control tissues (126).  Despite limited sample sizes in these studies (ranging from 19 
to 72 cases), all case-control studies indicated a positive association between HPV 
infection and colorectal neoplasia.  Estimates of the ORs associated with these studies 
ranged from 2.7 (95% CI = 1.1 to 6.2) to 9.1 (95% CI  = 3.7 to 22.3) (119, 124).  
 
In addition to these case-control studies, a recent study found that, among 56 HPV 
positive colorectal tumors, only 3.6% contained p53 mutations (127).  This is in contrast 
to the fact that approximately 50% of all colorectal cancers contain p53 mutations (128).  
The authors concluded that this is evidence that HPV may contribute to colorectal cancer 
through HPV-mediated p53 inactivation, thereby simulating a p53 mutation.  Based on 
this, HPV may play a role in the subset of colorectal cancers that lack p53 mutations.  
This is consistent with studies of oral carcinomas, which find the association with HPV to 
be strongest in the subset without p53 mutations (129).      
 
Large cohort studies, with sample sizes ranging from 21,222 to 104,760 cases of cervical 
cancer, have compared colorectal cancer risk in women with a history of cervical cancer 
to women in the general population (130-132).  Two of these studies reported no 
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association between cervical cancer and subsequent colorectal cancer (130, 131).  The 
other study found an increased risk of cancer of the anus/rectum among cervical cancer 
survivors, and an increased risk of colon cancer in women treated with radiotherapy but 
no increased risk of colon cancer in women who were not treated with radiotherapy 
(132).  This suggests that any increase in the risk of colon cancer among those with 
previous cervical cancer is related to radiation treatment and not because of a common 
etiology, HPV, for the two cancers.  
 
Due to the conflicting evidence concerning the association between colorectal cancer and 
HPV, further investigation is needed.  First, there are no studies of colorectal cancer and 
sexual risk factors, such as number of sexual partners, age at first intercourse, and history 
of anal intercourse.  Because HPV is a sexually transmitted virus, one would expect 
colorectal cancer to be positively associated with some or all of these sexual risk factors 
if HPV plays a role in colorectal carcinogenesis.  In addition, current case-control studies 
are small and do not adjust for potential confounding variables, such as age, sex, and 
smoking status.  Finally, no prospective studies have been done to establish the temporal 
association between HPV and colorectal neoplasia.  Therefore, despite some suggestive 
evidence of an association between HPV and colorectal neoplasia, large, well-designed 
studies are needed to test this hypothesis rigorously. 
 
Summary and recommendations 
  
It is notable that studies of colorectal cancer and infection have resulted in at least four 
possible candidates that may be involved in colorectal carcinogenesis.  This lack of 
specificity between one etiologic agent and colorectal cancer may be a clue that the 
relationship between colorectal cancer and infection is not due to any of these agents, but 
instead is tied to a general disruption in the microflora of the gut, resulting in an 
increased susceptibility to pathogenic infection.  Several review articles have discussed 
colorectal health in relation to normal flora in the gut (133-135).  This is an area that 
deserves further investigation, and any studies of this topic should be especially vigilant 
in assessing the temporal association between disruptions in the normal flora of the gut 
and colorectal cancer. 
 
In addition, the HPV and JC virus literature is dominated by studies that use PCR to 
detect viral DNA in colorectal neoplatic tissue.  Because PCR is susceptible to false 
positive results due to contamination, further tests, such as serologic assays, should be 
done for exposure assessment.  Another criticism of studies comparing tumor tissue in 
cases to normal tissue in controls is that the two types of tissues are not comparable, and 
the sensitivity and specificity of PCR-based testing techniques on normal control tissue is 
unknown.  Again, serologic tests would allow for more comparable exposure assessment 
between cases and controls.  However, serologic assays do not identify the site of 
infection, so site-specific testing is still an important component to evaluating the 
etiologic relationship between infectious agents and colorectal cancer. 
  
Also, three of the infectious agents reviewed, H. pylori, HPV, and JC virus, were first 
evaluated as causes of cancer in other parts of the body, with two of them (H. pylori and 
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HPV) having clear positive associations with other cancers.  This resulted in a whole host 
of studies assessing these agents’ possible role in multiple cancers.  However, neither 
HPV nor H. pylori is particularly suited to infect the colon, but hundreds of bacterial 
species that are adapted to colon have not been evaluated as possible causes of colorectal 
cancer.    
 
Several sets of guidelines for establishing causality between an exposure and disease 
have been proposed, with one of the most famous of these being the Bradford Hill criteria 
(136).  The Bradford Hill criteria are applied in epidemiologic studies and include the 
following: strength of the association (often measured by the magnitude of the odds ratio 
or relative risk estimate), temporality (exposure proceeds disease), consistency of studies, 
specificity (a one-to-one relationship in which the exposure leads to a single specific 
outcome), biological plausibility,  coherence with prior knowledge, biological gradient 
(sometimes considered a dose-effect), analogy, and experimentation.  A compilation of 
these criteria can be used to assess the likelihood that an exposure causes an outcome as 
opposed to being incidentally associated with the outcome.  Table 1 summarizes an 
evaluation of each infectious agent in relation to colorectal cancer using Hill’s criteria.  
Based in this table, it is clear that none of these agents show unequivocal, strong evidence 
for a causal association with colorectal cancer.  None have been evaluated to determine if 
the infectious agent precedes the development of colorectal cancer.  In addition, studies 
which assess viral or bacterial copy number in relation to disease severity, a way to 
evaluate the biological gradient criteria, are either limited or absent for these infectious 
agents.    
 
Colorectal cancer clearly does not have one single necessary and sufficient cause.  It is 
almost certain, on the basis of existing data that multiple pathways involving host 
genetics and environmental factors play a role in colorectal cancer carcinogenesis, and 
that subsets of colorectal cancer may be related to particular risk factors.  For example, 
much of colorectal cancer (close to 85% of cases) is characterized by chromosomal 
instability in which the tumor cells display aneuploidy, an unusual chromosome number 
(137).   However, approximately 15-17% of all colorectal carcinomas are characterized 
by microsatellite instability with mutations in, or methylation of, mismatch repair genes 
(138, 139).  This subset appears to be associated with smoking (140), and it is 
hypothesized that colorectal tumors with chromosomal versus microsatellite instability 
result from different carcinogenic pathways and may have different etiologies (137). 
 
Future studies of colorectal cancer and infectious agents should attempt to determine the 
subset of colorectal cancer that is most likely to be associated with the agent of interest, 
such as by studying the association between the subset colorectal cancer lacking p53 
mutations and HPV infection.  In addition, future studies should make the assessment of 
exposure more specific by focusing on the subtype of the agent of interest that is most 
pathogenic.  For example, studies should focus on CagA positive strains of H. pylori or S. 
bovis type I instead of collapsing across all subtypes of these organisms.  By focusing on 
more homogenous subsets of disease and subtypes of infectious agents, investigators may 
be able to increase the sensitivity of their studies to detect associations that may 
otherwise be masked by competing risk factors and misclassification of exposure status.  
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Also, prospective studies that establish temporality in the relationship between colorectal 
cancer and infection are necessary for evaluating causality. 
 
Linking cancer to infectious agents has created a whole new direction for cancer 
prevention.  Over the past 100 years, we have witnessed the eradication of infectious 
disease, such as smallpox, through vaccination, and we have seen the dramatic reduction 
in other vaccine-preventable diseases, such as measles and polio.  With the advent of the 
Hepatitis B vaccine and the more recent HPV vaccine, we are likely to see dramatic 
decreases in morbidity and mortality due to liver cancer and cervical cancer.  Through 
continued research in infectious agents and cancer, we may observe new associations as 
well as develop new effective means of prevention.  
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Table 1.  Evaluation of the association between colorectal cancer and H. pylori, S. bovis, JCV and HPV using the Bradford Hill criteria      
 H. pylori S. bovis JCV HPV 
Strength Meta-analysis OR=1.4  
+ 
ORs for detection of S. bovis in 
stool range from 1.0-10.7 
+ 
 
ORs for JCV DNA in cases vs. 
controls range from 1.0-6.2 
+ 
ORs for HPV DNA in cases vs. 
controls range from 2.7-9.1 
++ 
Temporality Not evaluated 
0 
Not evaluated 
0 
 
Not evaluated 
0 
Not evaluated 
0 
Consistency Most studies OR≥1 
++ 
S. bovis endocarditis studies 
consistently show elevated risks for 
colorectal neoplasia.  However, 
stool studies of colorectal cancer 
cases and controls are not 
consistent. 
++ 
 
Inconsistent study results 
+ 
Early studies do not detect HPV 
DNA in colorectal neoplastic tissue.  
Nine recent case-control studies 
consistently report an increased risk. 
++ 
Specificity H. pylori is a known cause of 
gastric cancer. 
+ 
S. bovis is a cause of septicemia 
and endocarditis. 
+ 
 
JCV is known to cause PML 
+ 
HPV is a known cause of several 
anogenital cancers. 
+ 
Biological Plausibility Association between gastrin, gastric 
H. pylori infection, and colorectal 
cancer is plausible.  Direct infection 
of the colon is unlikely. 
++ 
 
S. bovis is known to inhabit the 
colon, and molecular studies 
indicate that S. bovis proteins have 
carcinogenic properties. 
+++ 
JCV large T-antigen has carcinogenic 
properties, but its ability to infect the 
colon is under debate. 
+ 
HPV infects epithelial cells, and its 
oncogenic properties are well-
described, but the ability of HPV to 
enter the colon and rectum is 
debatable. 
++ 
Coherence Geographic distribution of 
colorectal cancer differs 
significantly from gastric cancer. 
+ 
Many colorectal cancers exhibit 
over-expression of COX-2.  S. 
bovis proteins upregulate COX-2 in 
vitro. 
+++ 
 
JCV is a neurotrophic virus and is 
very common in the population. 
+ 
Colorectal cancer occurs in epithelial 
cells, but the risk factors for HPV 
infection are not known for 
colorectal cancer. 
+ 
Biological gradient No evidence for gastrin. 
Not evaluated for H. pylori. 
0 
Not evaluated 
0 
One study finds viral copy number 
higher in cases than in controls. 
+ 
Not evaluated 
0 
Analogy H. pylori causes gastric cancer. 
++ 
H. pylori induces inflammation in 
the stomach, resulting in cellular 
proliferation and increased gastric 
cancer risk.  S. bovis could have a 
similar mechanism in the colon. 
++ 
 
SV40, another polyomavirus, is 
hypothesized to cause certain human 
cancers, including brain cancer.  
However, this has not been proven. 
+ 
HPV causes adenocarcinoma in the 
cervix. 
++ 
Experiment Not evaluated, but it is possible to 
treat H. pylori infection. 
0 
Not evaluated, but it is possible to 
treat S. bovis infection. 
0 
Not evaluated, and currently it is not 
possible to prevent JCV through 
vaccination. 
0 
Not evaluated, but it is possible 
through HPV vaccination studies. 
0 
0 = Not evaluated, + = Weak evidence, ++ = Moderate evidence, +++ = Strong evidence 
